Somewhat Favorable News Coverage Somewhat Unlikely to Affect Zogenix (ZGNX) Stock Price

Media coverage about Zogenix (NASDAQ:ZGNX) has been trending somewhat positive this week, Accern reports. The research group scores the sentiment of news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Zogenix earned a coverage optimism score of 0.15 on Accern’s scale. Accern also gave headlines about the company an impact score of 45.282765580739 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Here are some of the news headlines that may have impacted Accern’s rankings:

How to Become a New Pot Stock Millionaire

Zogenix stock opened at $40.15 on Monday. The firm has a market cap of $1,370.10, a PE ratio of -9.99 and a beta of 1.68. Zogenix has a fifty-two week low of $10.05 and a fifty-two week high of $45.85.

Zogenix (NASDAQ:ZGNX) last posted its quarterly earnings data on Tuesday, March 6th. The company reported ($1.14) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.97) by ($0.17). During the same quarter in the previous year, the firm posted ($0.95) EPS. sell-side analysts expect that Zogenix will post -3.12 earnings per share for the current year.

Several analysts have issued reports on the stock. Leerink Swann reiterated an “outperform” rating on shares of Zogenix in a research note on Sunday, March 4th. Mizuho reiterated a “buy” rating and issued a $51.00 target price on shares of Zogenix in a research note on Wednesday, March 7th. BidaskClub upgraded shares of Zogenix from a “hold” rating to a “buy” rating in a research note on Saturday, February 10th. ValuEngine upgraded shares of Zogenix from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Finally, Zacks Investment Research upgraded shares of Zogenix from a “sell” rating to a “hold” rating in a research note on Saturday, January 27th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $53.20.

In other news, Director Roger Hawley sold 35,000 shares of the firm’s stock in a transaction on Tuesday, March 13th. The shares were sold at an average price of $44.71, for a total transaction of $1,564,850.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 5.00% of the company’s stock.

TRADEMARK VIOLATION WARNING: This story was originally published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this story on another domain, it was illegally stolen and republished in violation of US and international copyright and trademark legislation. The original version of this story can be read at

Zogenix Company Profile

Zogenix, Inc is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Its lead product candidate, ZX008, is a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome.

Insider Buying and Selling by Quarter for Zogenix (NASDAQ:ZGNX)

Receive News & Ratings for Zogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix and related companies with's FREE daily email newsletter.

Leave a Reply